Learn more about the latest industry news and insights, along with Zeta India’s announcements, events, initiatives, and more — all in one place.
Learn more about the latest industry news and insights, along with Zeta India’s announcements, events, initiatives, and more — all in one place.
Category
Process simulation allows engineering teams to evaluate whether process requirements, equipment concepts, utilities and operating strategies will work together before expensive design and procurement decisions are finalised. As Indian biopharmaceutical manufacturers move beyond traditional vaccine
India’s biopharma manufacturing capabilities have long been recognised globally, particularly in generics and vaccines. But the opportunity ahead is broader. As Indian companies move into complex biologics, biosimilars, advanced therapies and global contract manufacturing, the
India’s biopharma sector is scaling fast. Vaccine manufacturing, biosimilars, and plasma-derived therapies are moving from pilot to commercial volumes, and facilities built for yesterday’s product mix are being asked to do far more than they
India’s biopharma industry is entering a transformative phase. From biosimilars and vaccines to cell culture technologies, fermentation-based products, and novel biologics, Indian manufacturers are rapidly scaling capabilities to meet both domestic and global demand. However,
A pharmaceutical process that performs flawlessly in the laboratory does not automatically perform the same way in commercial production. This reality sits at the heart of every scale-up project. Across the pharmaceutical industry, companies invest
India’s pharmaceutical industry continues to invest heavily in expansion. Whether driven by increasing demand, entry into regulated markets, diversification into biologics, or the addition of new manufacturing lines, expansion projects have become a strategic priority
Qualification has always been one of the most documentation-intensive phases in pharmaceutical engineering – but today’s projects demand a faster, smarter, and more connected approach. For decades, qualification activities such as Factory Acceptance Testing (FAT),
ZETA India is pleased to announce the successful completion of Batch 10 of our Industrial Training Programme on Bioprocess Engineering – Design and Operation of Bioprocess Equipment. We extend our heartfelt congratulations to our trainees
We were delighted to host 45 Biotechnology students and 4 faculty members from Dayananda Sagar University, Bangalore, at our Manufacturing Unit – I, located at #42, Budihal, Nelamangala, Bangalore, on Saturday, 25th April 2026. The
As the pharmaceutical industry expands to meet growing global demand for biologics, vaccines, and advanced therapies, companies are constantly planning new facilities and capacity expansions. However, planning a production expansion is rarely straightforward. Engineering teams
In biopharmaceuticals, quality is often discussed in the context of manufacturing. However, long before a product reaches the production floor, critical decisions have already been made – decisions that define how consistently, efficiently, and reliably
India’s Union Budget 2026 and the national biopharma initiatives are accelerating investment across advanced therapeutics, vaccines, and biologics manufacturing. Programs such as the government’s Biopharma Mission, aimed at strengthening translational research and domestic manufacturing capabilities,
ZETA India is pleased to announce the successful completion of Batch 10 of our Industrial Training Programme on Bioprocess Engineering – Design and Operation of Bioprocess Equipment. We extend our heartfelt congratulations to our trainees
We were delighted to host 45 Biotechnology students and 4 faculty members from Dayananda Sagar University, Bangalore, at our Manufacturing Unit – I, located at #42, Budihal, Nelamangala, Bangalore, on Saturday, 25th April 2026. The
On April 8, 2025, ZETA India had the honor of welcoming a delegation of Chemical Engineering students from Ramaiah Institute of Technology, Bengaluru, to our facility. The primary aim of the visit was to provide
ZETA India is delighted to announce the successful completion of the 4th batch of our Industrial Training Programme on Training in Biopharma Equipment. We extend our heartfelt congratulations to our trainees — Sanath Kumar P,
ZETA India is pleased to announce the successful completion of our first six-month training programme on Bioprocess Engineering – Design and Operation of Bioprocess Equipment. This achievement marks a significant milestone in our ongoing commitment
The biopharmaceutical market in the Asian region shows enormous growth potential. The internationally active ZETA Group has established itself as an end-to-end solution. ZETA Biosystem aims to improve its integration into the international ZETA Group
As the pharmaceutical industry expands to meet growing global demand for biologics, vaccines, and advanced therapies, companies are constantly planning new facilities and capacity expansions. However, planning a production expansion is rarely straightforward. Engineering teams
What does it take to scale large-scale biopharmaceutical production fast without sacrificing compliance, robustness, or product quality? In this case study, see how a globally recognised vaccine manufacturer executed a major capacity expansion (new bioreactor
As production leaders in biopharma companies, you will appreciate the complex journey from bench-scale research to full-scale GMP manufacturing. At ZETA, we know first-hand that scaling up a bioreactor process is never simply a matter
Process simulation allows engineering teams to evaluate whether process requirements, equipment concepts, utilities and operating strategies will work together before expensive design and procurement decisions are finalised. As Indian biopharmaceutical manufacturers move beyond traditional vaccine
India’s biopharma manufacturing capabilities have long been recognised globally, particularly in generics and vaccines. But the opportunity ahead is broader. As Indian companies move into complex biologics, biosimilars, advanced therapies and global contract manufacturing, the
India’s biopharma sector is scaling fast. Vaccine manufacturing, biosimilars, and plasma-derived therapies are moving from pilot to commercial volumes, and facilities built for yesterday’s product mix are being asked to do far more than they
A pharmaceutical process that performs flawlessly in the laboratory does not automatically perform the same way in commercial production. This reality sits at the heart of every scale-up project. Across the pharmaceutical industry, companies invest
India’s Union Budget 2026 and the national biopharma initiatives are accelerating investment across advanced therapeutics, vaccines, and biologics manufacturing. Programs such as the government’s Biopharma Mission, aimed at strengthening translational research and domestic manufacturing capabilities,
India’s biopharmaceutical industry is entering a new phase of expansion. Beyond its established leadership in vaccines and biosimilars, the country is now investing across advanced modalities, including monoclonal antibodies, cell and gene therapies, plasma products,
India’s pharmaceutical manufacturing sector is experiencing rapid growth, reinforcing its position as the “pharmacy of the world.” According to the EY-Parthenon–OPPI report, pharma exports reached $27.85 billion in FY 2023–24, nearing the $30 billion mark.
The global fermenters market reached $1.80 billion in 2025 and is projected to reach $2.63 billion by 2032 at a 5.60% CAGR, driven by rising biopharma demand for vaccines, biosimilars, and recombinant proteins. In the
In the highly regulated and complex pharma and biotech sectors, fragmented engineering processes often lead to costly delays, compliance issues, and inefficient facilities that hinder production scale-up. Project managers, production heads, and CEOs need a
After the founders closed their seed round for a biotech startup, it felt like the hardest part was behind them. The upstream platform for a new class of recombinant proteins had worked beautifully in the
Fermentation is the backbone of contemporary biopharmaceutical production, enabling manufacturers to create a wide range of products, from life-saving vaccines to high-value APIs and recombinant proteins. For production and project managers, mastering the principles of
For procurement heads and project managers in the pharmaceutical industry, few choices are as consequential as selecting the right mixer or agitator supplier. At the heart of every bioreactor and process vessel, the agitator must
India’s biopharma industry is entering a transformative phase. From biosimilars and vaccines to cell culture technologies, fermentation-based products, and novel biologics, Indian manufacturers are rapidly scaling capabilities to meet both domestic and global demand. However,
India’s pharmaceutical industry continues to invest heavily in expansion. Whether driven by increasing demand, entry into regulated markets, diversification into biologics, or the addition of new manufacturing lines, expansion projects have become a strategic priority
Qualification has always been one of the most documentation-intensive phases in pharmaceutical engineering – but today’s projects demand a faster, smarter, and more connected approach. For decades, qualification activities such as Factory Acceptance Testing (FAT),
In biopharmaceuticals, quality is often discussed in the context of manufacturing. However, long before a product reaches the production floor, critical decisions have already been made – decisions that define how consistently, efficiently, and reliably
What to look for – and how to avoid common pitfalls in greenfield and brownfield facilities Whether you are building a new biopharma facility from the ground up or upgrading an existing one, the choice
Sustainability is no longer a side conversation in the pharmaceutical industry — it is becoming a core design principle. As global demand for medicines rises and manufacturing scales up, the environmental footprint of pharma production
A simulation-first approach is quickly becoming non‑negotiable in biopharma facilities – both greenfield and brownfield projects. It is one of the few levers that can simultaneously de‑risk capex, compress timelines and stabilise operations over a
As production leaders in biopharma companies, you will appreciate the complex journey from bench-scale research to full-scale GMP manufacturing. At ZETA, we know first-hand that scaling up a bioreactor process is never simply a matter
Selecting the Right Agitator: What Matters Most for Pharma Procurement and Project Teams ZETA Magnetic Agitators: A Versatile, Proven Product Family At the core of ZETA’s offering is an impressive portfolio of magnetic agitators, including
Driving Global Readiness in Indian Pharma: ZETA India’s Roadmap for Annex 1 Compliance and FDA’s Aseptic Guidance India’s pharmaceutical sector stands at a global inflexion point. Renowned as the world’s pharmacy, the nation’s sterile manufacturing
Advancing Simulation-Driven Engineering In February 2026, ZETA India connected with industry professionals through a focused roadshow in Hyderabad (03 Feb) and Bengaluru (05 Feb), bringing simulation-led innovation closer to customers and partners. The events saw
The spirit of tradition, unity, and gratitude filled the atmosphere as ZETA India – Unit 1 joyfully celebrated Ayudha Pooja 2025 with great enthusiasm. This significant occasion honors the tools, machines, and technologies that enable
We are pleased to have been a part of Pharma Pro & Pack 2025 in Hyderabad, where ZETA India showcased its latest innovations in the biopharma and pharma sectors. During the event, ZETA highlighted its
ZETA India is pleased to report the successful conclusion of an industrial visit by 45 biotechnology students from B.S. Abdur Rahman Crescent Institute of Science and Technology, Chennai, which took place on Tuesday, 22nd October
We work closely with biopharmaceutical organizations to deliver reliable, precise, and high-quality bioprocess engineering solutions.
